There was a significantly worse OS for clinical tumor stages III-IV (HR: 5.92, 95% CI: 4.00-8.77) compared to tumor stages 0-II, and worse OS for tumors that were ER-negative (HR: 2.04, 95% CI: 1.38–3.02), PR-negative (HR: 2.33, 95% CI: 1.59–3.43), or triple-negative (HR: 2.38, 95% CI: 1.55–3.66). The gene discussed is ESR1; the disease is neoplasm.